How Long COVID May Reshape the Brain; EEG as Fentanyl Biomarker; Novel ALS Target?

Vanderbilt University’s Wes Ely, MD, looked at ways long COVID may reshape the brain and how that might be treated. (Washington Post)

A deep learning model showed that predicting response to anti-seizure medications based on clinical information was feasible. (JAMA Neurology)

A genetic quirk that helped clear amyloid in mouse brains may lead to a new druggable Alzheimer’s target. (Brain)

An EEG biomarker may help monitor respiratory effects of fentanyl use, a small experiment suggested. (PNAS Nexus)

Final data from the phase III ULTIMATE I and II trials showed that investigational ublituximab led to lower annualized relapse rates and fewer brain lesions than teriflunomide (Aubagio) in relapsing multiple sclerosis. (New England Journal of Medicine)

Novartis suspended branaplam dosing in the phase IIb VIBRANT-HD trial of Huntington’s disease after peripheral neuropathy safety signals emerged, the company said in a letter to the community.

Deep brain stimulation of the nucleus accumbens showed promise against loss-of-control food cravings, a pilot study showed. (Nature Medicine)

Brain-injured patients who received neurocritical care had a 17% relative risk reduction in mortality and unfavorable functional outcomes compared with those who had general care in critical care settings, a meta-analysis found. (JAMA Neurology)

Intelligence and cognitive flexibility were improved in overweight or obese children with 20 weeks of relatively high-intensity exercise, the ActiveBrains trial showed. (JAMA Network Open)

Animal studies suggested apolipoprotein B-100 may be a novel therapeutic target for sporadic ALS. (Brain Communications)

An artificial intelligence model detected Parkinson’s disease from nocturnal breathing patterns. (Nature Medicine)